Identifying and Documenting Adverse Events at Clinical Study Sites

Improving adverse event reporting can lead to improved safety profiles and, consequently, fewer drugs pulled from the market.

Related Content:

View from BrusselsApplied Clinical Trials-05-01-2002

Dragging the EU into a More Health-Conscious Post-COVID Dynamic

Europe's Eternal Struggle with Safety and Innovation

Another European Gap that Needs to be Filled: Advanced Diagnostics